Oncology Molecular Diagnostics

Oncology Molecular Diagnostics

Global Oncology Molecular Diagnostics Market to Reach US$10.8 Billion by 2030

The global market for Oncology Molecular Diagnostics estimated at US$5.2 Billion in the year 2023, is expected to reach US$10.8 Billion by 2030, growing at a CAGR of 11.1% over the analysis period 2023-2030. Breast Cancer, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Colorectal Cancer segment is estimated at 14.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 14.2% CAGR

The Oncology Molecular Diagnostics market in the U.S. is estimated at US$1.4 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 14.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.7% and 9.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.5% CAGR.

Global Oncology Molecular Diagnostics Market – Key Trends & Drivers Summarized

What Is Oncology Molecular Diagnostics and Why Is It Transforming Cancer Care?

Oncology molecular diagnostics refers to the use of molecular biology techniques to analyze genetic mutations, biomarkers, and other molecular characteristics in cancer cells. This approach enables early and accurate cancer detection, prognosis, and personalized treatment plans by identifying specific mutations or abnormalities at the molecular level. Molecular diagnostics are essential for precision oncology, where therapies are tailored to an individual`s genetic profile, providing more effective and targeted cancer treatment. Techniques such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid biopsy are commonly employed in oncology molecular diagnostics, allowing oncologists to detect genetic variations in solid tumors, hematological cancers, and metastatic diseases. As cancer treatment moves towards more personalized and molecularly driven approaches, the role of molecular diagnostics has become indispensable in improving patient outcomes and survival rates.

How Are Technological Innovations Accelerating the Adoption of Molecular Diagnostics in Oncology?

Technological advancements have played a crucial role in expanding the scope and capabilities of oncology molecular diagnostics. Next-generation sequencing (NGS) has revolutionized the field, enabling the simultaneous analysis of multiple genes and genetic mutations in a single test. This innovation allows for comprehensive genomic profiling, which is essential for identifying actionable mutations that can guide targeted therapy decisions. Liquid biopsy is another cutting-edge technology that is gaining traction, offering a non-invasive method for detecting cancer mutations from circulating tumor DNA (ctDNA) in the blood. This approach is particularly valuable in monitoring treatment response and detecting relapse in real time. Advances in bioinformatics and AI-powered data analysis are also enhancing the accuracy and speed of molecular diagnostics, making it easier to interpret complex genomic data. These technological innovations are making molecular diagnostics faster, more accessible, and increasingly vital in routine oncology care.

Why Is Molecular Diagnostics Crucial for Precision Oncology and Patient Outcomes?

Molecular diagnostics is central to the growing field of precision oncology, where cancer treatments are personalized based on the genetic makeup of an individual’s tumor. By identifying specific mutations and biomarkers, molecular diagnostics allow oncologists to select targeted therapies that directly interfere with the cancer-driving genetic alterations, thereby improving the effectiveness of treatment and minimizing side effects. For example, patients with mutations in genes like EGFR, ALK, or BRCA can be treated with specific targeted therapies or immunotherapies that are more likely to work based on their molecular profile. Additionally, molecular diagnostics enable early cancer detection, increasing the chances of successful intervention and treatment. Beyond diagnosis, these tests are used for monitoring minimal residual disease (MRD), tracking response to therapies, and detecting early signs of cancer recurrence, ultimately improving patient survival rates and quality of life.

What Factors Are Driving Growth in the Oncology Molecular Diagnostics Market?

The growth in the oncology molecular diagnostics market is driven by several factors, most notably the rising incidence of cancer and the increasing demand for precision medicine. As the global cancer burden grows, healthcare providers are increasingly relying on molecular diagnostics to guide treatment decisions, leading to a surge in demand for advanced testing solutions. Technological advancements, including next-generation sequencing (NGS), liquid biopsy, and AI-driven data analysis, are making these diagnostics more precise and accessible. The shift towards personalized cancer therapies, such as targeted therapies and immunotherapies, is another major growth driver, as molecular diagnostics are essential for identifying patients who will benefit from these treatments. Moreover, increased regulatory approvals for companion diagnostics—tests that help match patients with the right therapies—are fueling market expansion. The growing focus on early detection and monitoring of cancer, alongside increasing investments in research and development, is expected to sustain robust growth in this market over the coming years.

Select Competitors (Total 12 Featured) -
  • Abbott Laboratories
  • Bayer Healthcare AG
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Cepheid, Inc.
  • Danaher Corporation
  • Hologic, Inc.
  • Leica Biosystems Inc.
  • Qiagen NV
  • Roche Diagnostics (Schweiz) AG
  • Siemens Healthineers
  • Sysmex Corporation
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Oncology Molecular Diagnostics – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Cancer Worldwide Drives Demand for Advanced Oncology Molecular Diagnostics for Early Detection
Increased Focus on Personalized and Precision Medicine Expands Addressable Market for Oncology Molecular Diagnostics
Advancements in Liquid Biopsy Technology Propel Growth of Non-Invasive Molecular Diagnostics in Oncology
The Integration of Next-Generation Sequencing (NGS) in Oncology Diagnostics Spurs Adoption in Precision Oncology
Growing Demand for Companion Diagnostics Strengthens the Business Case for Oncology Molecular Diagnostics Solutions
Rising Use of Biomarker-Based Diagnostics Accelerates Demand for Molecular Tests in Targeted Cancer Therapies
Increasing Application of Molecular Diagnostics in Immuno-Oncology Expands Market Growth Opportunities
Technological Advancements in Point-of-Care Diagnostics Drive the Adoption of Molecular Oncology Solutions in Clinical Settings
Shift Toward Liquid Biopsies for Cancer Monitoring Generates Demand for Oncology Molecular Diagnostics
Growing Demand for Multi-Gene Panel Testing in Cancer Diagnostics Strengthens Business Case for Advanced Molecular Solutions
Rising Awareness of Genetic Predisposition and Hereditary Cancer Testing Spurs Growth in Molecular Oncology Diagnostics
Increasing Use of AI and Machine Learning in Molecular Diagnostics Expands the Market for Predictive Oncology Solutions
Rise of Consumer Genomics and Direct-to-Consumer Genetic Testing Drives Demand for Oncology Molecular Diagnostics
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Oncology Molecular Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Oncology Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Liver Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: USA Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: USA 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: USA Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: USA 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
CANADA
TABLE 35: Canada Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Canada 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 38: Canada Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Canada 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
JAPAN
Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 41: Japan Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Japan 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 44: Japan Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Japan Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Japan 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
CHINA
Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 47: China Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: China Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: China 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 50: China Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: China Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: China 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
EUROPE
Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 53: Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Oncology Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Europe 16-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Europe 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 59: Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Europe Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Europe 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
FRANCE
Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 62: France Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: France Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: France 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 65: France Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: France Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: France 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
GERMANY
Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 68: Germany Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Germany 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 71: Germany Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Germany Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Germany 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
ITALY
TABLE 74: Italy Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Italy 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 77: Italy Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Italy Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Italy 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
UNITED KINGDOM
Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 80: UK Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: UK Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: UK 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 83: UK Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: UK Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: UK 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
SPAIN
TABLE 86: Spain Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Spain 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 89: Spain Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Spain Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Spain 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
RUSSIA
TABLE 92: Russia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Russia 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 95: Russia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Russia Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Russia 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Rest of Europe 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Rest of Europe Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Rest of Europe 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Asia-Pacific 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
AUSTRALIA
Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 113: Australia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Australia 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 116: Australia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: Australia Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: Australia 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
INDIA
Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 119: India Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: India Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: India 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 122: India Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: India Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: India 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 125: South Korea Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: South Korea 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 128: South Korea Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: South Korea Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: South Korea 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Rest of Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
LATIN AMERICA
Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 137: Latin America Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Oncology Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Latin America 16-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Latin America 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 143: Latin America Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Latin America Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Latin America 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 146: Argentina Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Argentina 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 149: Argentina Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Argentina Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Argentina 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
BRAZIL
TABLE 152: Brazil Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Brazil 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 155: Brazil Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Brazil Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Brazil 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
MEXICO
TABLE 158: Mexico Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Mexico 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 161: Mexico Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Mexico Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Mexico 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Rest of Latin America 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 168: Rest of Latin America Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Rest of Latin America 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
MIDDLE EAST
Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 170: Middle East Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Oncology Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Middle East 16-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Middle East 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 176: Middle East Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Middle East Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Middle East 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
IRAN
TABLE 179: Iran Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Iran 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 182: Iran Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Iran Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Iran 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
ISRAEL
TABLE 185: Israel Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: Israel 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 188: Israel Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Israel Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: Israel 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Saudi Arabia 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: Saudi Arabia Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: Saudi Arabia 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 197: UAE Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: UAE 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 200: UAE Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: UAE Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: UAE 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: Rest of Middle East 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: Rest of Middle East Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: Rest of Middle East 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
AFRICA
Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 209: Africa Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 211: Africa 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 212: Africa Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 213: Africa Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 214: Africa 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings